How Covid failed to derail the FDA
Average US review times match absolute approval numbers in remaining unaffected by the Covid pandemic.
What now for low-cost PD-(L)1 competition?
The prospects for Chinese competitors, ongoing controversy in cervical cancer and a super-fast approval take centre stage.
Digging into biopharma’s big buyout areas
Cancer, rare diseases and neurology targets account for a big chunk of biopharma's buyouts, with interest showing no sign of waning.
Biding your time buying is becoming costly
Companies with late-stage assets have been attracting ever higher price tags over the past five years, Evaluate Vantage finds.
Rare disease and neurology takeouts tick higher
Biopharma's growing appetite for higher-risk areas prompts a shift in dealmaking strategies, our latest deep dive into M&A data finds.
Covid infects biopharma’s biggest sellers
The Biontech/Pfizer pandemic vaccine sneaks into the 10 biggest-ever cumulative sellers, while Merck & Co’s Keytruda vaults to second place.
The biggest launches of 2022: a reboot
New Alzheimer’s launches are all but ruled out, so projects from Lilly, Alynlam and Roche top 2022’s biggest hopes.
